Keyphrases
Signaling Cascades
100%
Mitogen-activated Protein Kinase
100%
Resistance Mechanisms
100%
Glucocorticoid Resistance
100%
Pediatric Leukemia
100%
Prednisolone
50%
Knockdown
33%
MEK1
33%
Pediatric Acute Lymphoblastic Leukemia
33%
Relapsed Disease
33%
Acute Lymphoblastic Leukemia Cells
33%
Epigenetic Modification
16%
Chemotherapy
16%
Xenograft Model
16%
Knock
16%
MEK2
16%
MEK Inhibitor (MEKi)
16%
Genome-scale
16%
Leukemia Patients
16%
Distinct Mechanism
16%
Short Hairpin RNA (shRNA)
16%
Glucocorticoid Receptor
16%
Relapsed or Refractory Acute Myeloid Leukemia
16%
Leukemia Cell Lines
16%
Genetic Changes
16%
Acquired Resistance
16%
Enhanced Response
16%
ERK Phosphorylation
16%
Chemosensitivity
16%
Trametinib
16%
Chemotherapy Agents
16%
MEK4
16%
Prednisolone Resistance
16%
Medicine and Dentistry
Pediatrics
100%
Kinase Signaling
100%
Mitogen-Activated Protein Kinase
100%
Leukemia
100%
Glucocorticoid
100%
Acute Lymphoblastic Leukemia
83%
Prednisolone
66%
Mediator
33%
Diseases
33%
In Vitro
16%
Xenograft
16%
Short Hairpin RNA
16%
Leukemia Cell
16%
Chemotherapy Agent
16%
Protein P53
16%
Leukemia Cell Line
16%
Chemosensitivity
16%
Glucocorticoid Receptor
16%
Trametinib
16%
Biochemistry, Genetics and Molecular Biology
Mitogen-Activated Protein Kinase
100%
Glucocorticoid
100%
Prednisolone
66%
Mediator
33%
Epigenetics
16%
Genetics
16%
P53
16%
Glucocorticoid Receptor
16%
Small Hairpin RNA
16%
Chemosensitivity
16%
Trametinib
16%
Small Interfering RNA
16%
Immunology and Microbiology
Mitogen
100%
Glucocorticoid
100%
Prednisolone
66%
Mediator
33%
Xenograft
16%
P53
16%
Leukemia Cell
16%
Leukemia Cell Line
16%
Chemosensitivity
16%
Trametinib
16%
In Vitro
16%
Ribonucleic Acid
16%
Neuroscience
Mitogen-Activated Protein Kinase
100%
Glucocorticoid
100%
Prednisolone
66%
In Vitro
16%
In Vivo
16%
P53
16%
Cell Line
16%
Small Hairpin RNA
16%
Glucocorticoid Receptor
16%
Trametinib
16%